BRIEF-Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology For Oligomer-Selective Antibodies
Reuters
Yesterday
BRIEF-Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology For Oligomer-Selective Antibodies
Dec 2 (Reuters) - Acumen Pharmaceuticals Inc ABOS.O:
ACUMEN PHARMACEUTICALS HIGHLIGHTS ENHANCED BRAIN DELIVERY™ TECHNOLOGY FOR OLIGOMER-SELECTIVE ANTIBODIES AND RECRUITMENT STRATEGIES FOR PHASE 2 ALTITUDE-AD CLINICAL TRIAL AT 18TH ANNUAL CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
Source text: ID:nGNX2RQvlL
Further company coverage: ABOS.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.